These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 31865273)
1. Long-term real-world evidence for sustained clinical benefits of fingolimod following switch from natalizumab. Ziemssen T; Lang M; Tackenberg B; Schmidt S; Albrecht H; Klotz L; Haas J; Lassek C; Cornelissen C; Ettle B; Mult Scler Relat Disord; 2020 Apr; 39():101893. PubMed ID: 31865273 [TBL] [Abstract][Full Text] [Related]
2. Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION-A 2-Year, Multicenter, Observational, Cohort Study. Butzkueven H; Giacomini PS; Cohan S; Ziemssen T; Sienkiewicz D; Zhang Y; Geissbühler Y; Silva D; Tomic D; Kropshofer H; Trojano M Brain Sci; 2022 Feb; 12(2):. PubMed ID: 35203978 [TBL] [Abstract][Full Text] [Related]
3. Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod. Diem L; Nedeltchev K; Kahles T; Achtnichts L; Findling O Ther Adv Neurol Disord; 2018; 11():1756286418791103. PubMed ID: 30116299 [TBL] [Abstract][Full Text] [Related]
4. Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit-Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA. Ziemssen T; Lang M; Tackenberg B; Schmidt S; Albrecht H; Klotz L; Haas J; Lassek C; Medin J; Cornelissen C; Neurotherapeutics; 2018 Jan; 15(1):190-199. PubMed ID: 29274026 [TBL] [Abstract][Full Text] [Related]
5. Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study. Cohen M; Maillart E; Tourbah A; De Sèze J; Vukusic S; Brassat D; Anne O; Wiertlewski S; Camu W; Courtois S; Ruet A; Debouverie M; Le Page E; Casez O; Heinzlef O; Stankoff B; Bourre B; Castelnovo G; Rico A; Berger E; Camdessanche JP; Defer G; Clavelou P; Al Khedr A; Zephir H; Fromont A; Papeix C; Brochet B; Pelletier J; Lebrun C; JAMA Neurol; 2014 Apr; 71(4):436-41. PubMed ID: 24566807 [TBL] [Abstract][Full Text] [Related]
6. Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom. Spelman T; Herring WL; Zhang Y; Tempest M; Pearson I; Freudensprung U; Acosta C; Dort T; Hyde R; Havrdova E; Horakova D; Trojano M; De Luca G; Lugaresi A; Izquierdo G; Grammond P; Duquette P; Alroughani R; Pucci E; Granella F; Lechner-Scott J; Sola P; Ferraro D; Grand'Maison F; Terzi M; Rozsa C; Boz C; Hupperts R; Van Pesch V; Oreja-Guevara C; van der Walt A; Jokubaitis VG; Kalincik T; Butzkueven H; Pharmacoeconomics; 2022 Mar; 40(3):323-339. PubMed ID: 34921350 [TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY). Cohan SL; Moses H; Calkwood J; Tornatore C; LaGanke C; Smoot KE; Meka V; Okwuokenye M; Hotermans C; Mendoza JP; Mann MK; Meltzer LA Mult Scler Relat Disord; 2018 May; 22():27-34. PubMed ID: 29524759 [TBL] [Abstract][Full Text] [Related]
9. Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis. Zhu C; Zhou Z; Roos I; Merlo D; Kalincik T; Ozakbas S; Skibina O; Kuhle J; Hodgkinson S; Boz C; Alroughani R; Lechner-Scott J; Barnett M; Izquierdo G; Prat A; Horakova D; Kubala Havrdova E; Macdonell R; Patti F; Khoury SJ; Slee M; Karabudak R; Onofrj M; Van Pesch V; Prevost J; Monif M; Jokubaitis V; van der Walt A; Butzkueven H; J Neurol Neurosurg Psychiatry; 2022 Dec; 93(12):1330-1337. PubMed ID: 36261289 [TBL] [Abstract][Full Text] [Related]
10. Fingolimod after natalizumab and the risk of short-term relapse. Jokubaitis VG; Li V; Kalincik T; Izquierdo G; Hodgkinson S; Alroughani R; Lechner-Scott J; Lugaresi A; Duquette P; Girard M; Barnett M; Grand'Maison F; Trojano M; Slee M; Giuliani G; Shaw C; Boz C; Spitaleri DL; Verheul F; Haartsen J; Liew D; Butzkueven H; Neurology; 2014 Apr; 82(14):1204-11. PubMed ID: 24610329 [TBL] [Abstract][Full Text] [Related]
11. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. Kalincik T; Horakova D; Spelman T; Jokubaitis V; Trojano M; Lugaresi A; Izquierdo G; Rozsa C; Grammond P; Alroughani R; Duquette P; Girard M; Pucci E; Lechner-Scott J; Slee M; Fernandez-Bolanos R; Grand'Maison F; Hupperts R; Verheul F; Hodgkinson S; Oreja-Guevara C; Spitaleri D; Barnett M; Terzi M; Bergamaschi R; McCombe P; Sanchez-Menoyo J; Simo M; Csepany T; Rum G; Boz C; Havrdova E; Butzkueven H; Ann Neurol; 2015 Mar; 77(3):425-35. PubMed ID: 25546031 [TBL] [Abstract][Full Text] [Related]
12. Real-world persistence and benefit-risk profile of fingolimod over 36 months in Germany. Ziemssen T; Lang M; Tackenberg B; Schmidt S; Albrecht H; Klotz L; Haas J; Lassek C; Couto CA; Findlay JA; Cornelissen C; Neurol Neuroimmunol Neuroinflamm; 2019 May; 6(3):e548. PubMed ID: 30882022 [TBL] [Abstract][Full Text] [Related]
13. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Alping P; Frisell T; Novakova L; Islam-Jakobsson P; Salzer J; Björck A; Axelsson M; Malmeström C; Fink K; Lycke J; Svenningsson A; Piehl F Ann Neurol; 2016 Jun; 79(6):950-8. PubMed ID: 27038238 [TBL] [Abstract][Full Text] [Related]
14. Safety and Effectiveness of Fingolimod in Real-World Multiple Sclerosis Portuguese Patients. Ribeiro de Barros AH; Fiadeiro Sequeira JP; Lopes de Sousa AS; Cheganças Capela CM; Gomes Pedrosa RM; Dos Santos Manita MA Clin Neuropharmacol; 2018; 41(4):129-135. PubMed ID: 29927805 [TBL] [Abstract][Full Text] [Related]
15. Second-line therapy with fingolimod for relapsing-remitting multiple sclerosis in clinical practice: the effect of previous exposure to natalizumab. Bianco A; Patanella AK; Nociti V; Marti A; Frisullo G; Plantone D; De Fino C; Fetta A; Batocchi AP; Rossini PM; Mirabella M Eur Neurol; 2015; 73(1-2):57-65. PubMed ID: 25402749 [TBL] [Abstract][Full Text] [Related]
16. The PANGAEA study design - a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice. Ziemssen T; Kern R; Cornelissen C BMC Neurol; 2015 Jun; 15():93. PubMed ID: 26084334 [TBL] [Abstract][Full Text] [Related]
17. Switching to fingolimod in PREFERMS: Effect of treatment history and naïvety on clinical, MRI and treatment satisfaction outcomes Hunter SF; Thomas FP; Cascione M; Williams IM; Meng X; Schofield L; Weiss JL; Tenenbaum N; Cree BAC; Mult Scler Relat Disord; 2020 Oct; 45():102346. PubMed ID: 32717684 [TBL] [Abstract][Full Text] [Related]
18. Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients. Leurs CE; van Kempen ZL; Dekker I; Balk LJ; Wattjes MP; Rispens T; Uitdehaag BM; Killestein J Mult Scler; 2018 Oct; 24(11):1453-1460. PubMed ID: 28823223 [TBL] [Abstract][Full Text] [Related]
19. Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study. Barrero F; Mallada-Frechin J; Martínez-Ginés ML; Marzo ME; Meca-Lallana V; Izquierdo G; Ara JR; Oreja-Guevara C; Meca-Lallana J; Forero L; Sánchez-Vera I; Moreno MJ; PLoS One; 2020; 15(4):e0230846. PubMed ID: 32240213 [TBL] [Abstract][Full Text] [Related]
20. Rituximab for people with multiple sclerosis. Filippini G; Kruja J; Del Giovane C Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013874. PubMed ID: 34748215 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]